Dihydrofolate reductase (Dhfr; EC 1.5.1.3) catalyzes the reduction of dihydrofolate to tetrahydrofolate, a cofactor required in purine, pyrimidine, and glycine biosynthesis (10) . Several folate analogs, such as methotrexate and trimethoprim, which powerfully inhibit Dhfr and result in cell death, have been described previously (10, 11) . These agents bind tightly to the catalytic site of the enzyme in a region found, from X-ray diffraction analysis, to comprise a hydrophobic substrate binding pocket (25, 41) . However, the use of these agents as antineoplastic or antibacterial compounds is compromised by the emergence of cells resistant to the effects of the drugs. Resistance can result from any of three mechanisms which may act separately or in concert. Overproduction of the enzyme (2, 4, 24) , caused by increases in the level of transcription (30) or by amplification of the Dhfr gene (1, 30) , results in a drug-resistant phenotype in bacterial and mammalian cells. In addition, the effects of the folate analogs can be overcome by mutations which affect the transport of the folate analogs across the cell membrane (22) or by the synthesis of Dhfrs having reduced affinities for the inhibitors (18, 22) . Analyses of the mutant Dhfrs found in a trimethoprim-resistant strain of Escherichia coli (5) and in a methotrexate-resistant line of mouse 3T6 cells (32) have shown that the altered Dhfr found in each organism differs from the wild-type enzyme at a single amino acid in the region of the enzyme thought to comprise the hydrophobic binding pocket essential for inhibitor binding (25, 41) .
In 1972, Fleming and his colleagues (16) reported the presence of bacterial R-plasmids which conferred high levels of trimethoprim resistance upon their hosts. Later reports (3, 33) demonstrated that the R-plasmids encoded a Dhfr which was resistant to the antifolate drugs. Two forms of R-factor Dhfr based on differential susceptibility to trimethoprim and related antifolate compounds have been described (27) . The type I Dhfr, typified by the R483-encoded enzyme, is inhibited by trimethoprim at levels 1,000-fold greater than those which inhibit the chromosomally encoded bacterial enzyme and has a native molecular weight of 35,000, which is twice that of the chromosomally encoded Dhfr (27) . Expression of the type I enzyme in an E. coli minicell system has demonstrated that the subunit molecular weight is approximately 18 ,000, suggesting that the active form of the enzyme is a dimer (17 (20) . The derivation of the trp expression plasmid pSRCexl6 has been previously reported (26) .
DNA manipulations. Small-scale plasmid DNA was prepared by the method of Birnboim and Doly (8) . The methods of digesting DNA, ligating DNA fragments, and transforming plasmid DNA into E. coli have been previously described (20, 21) . DNA was digested and electrophoresed on acrylamide or agarose gels for preparation of fragments and analysis. Large DNA fragments were isolated from 0.6% low-melting-temperature agarose gels in Tris-acetate buffer (13) . DNA fragments were stained with ethidium bromide and visualized by UV light, and the bands were cut out. DNA fragments from agarose gels were diluted to 0.1% agarose with water and then heated to 65C. After the fragments were cooled to 37°C, restriction or ligation buffer w,as added, and further manipulations were performed as described above. DNA fragments from acrylamide gels were electroeluted as described previously (20, 21 (23) . The inhibition of activity by trimethoprim was measured by plotting fractional inhibition versus trimethoprim concentration and interpolating to obtain the 50% inhibitory concentration (27) .
RESULTS
Isolation of a DNA fragment encompassing type I Dhfr. The trimethoprim-resistant E. coli strain containing plasmid R483 was originally isolated from a calf undergoing trimethoprim treatment by Fleming and his colleagues (16) . Subsequent work showed that the gene encoding the type I Dhfr is contained within transposon Tn7 and is closely linked to a streptomycin resistance marker (7, 11) . To isolate the Dhfr gene, Rfactor DNA isolated from E. coli J53F(R483) was cleaved with BamHI and EcoRI, and ligated to pBR322 which had been similarly cleaved. Competent E. coli 294 cells were transformed with the ligation mix and were plated onto L broth plates containing ampicillin and trimethoprim. No colonies arose from control ligations lacking R483 inserts; however trimethoprim-resistant colonies did arise from ligations containing R483 DNA digested with EcoRI plus BamHI. Plasmid DNA was isolated from these colonies and analyzed, using several restriction endonucleases. All trimethoprim-resistant colonies harbored plasmids carrying identical inserts of 35 kilobases (kb), consisting of a 30-kb EcoRI fragment and a 5.4-kb EcoRI-BamHI fragment. This plasmid, designated pRB483, is shown in Fig. la.
To further localize the trimethoprim resistance gene, extraneous sequences were removed from pRB483 by treatment of the plasmid with PvuII under conditions which produced incomplete digestion of the DNA. The partially cleaved DNAs were mixed with T4 DNA ligase at low DNA concentrations and used to transform competent E. coli 294. Plasmid DNA was isolated from trimethoprim-resistant colonies and analyzed. The smallest plasmid isolated, pTM4 (Fig. lb) , retained the 5.4-kb EcoRIBamHI fragment and contained a 6-kb EcoRI fragment. To determine which of the two insert fragments encoded the trimethoprim resistance marker, the 6-kb EcoRI and the 5.4-kb EcoRIBamHI fragments of pTM4 were separately subcloned into pBR322. Trimethoprim-resistant colonies were obtained from cells containing the 6-kb EcoRI fragment inserted into the vector but not from a vector containing the 5.4-kb EcoRIBamHI fragment.
To obtain a smaller fragment sufficient for sequence analysis of the DNA fragment encom- passing the type I Dhfr, we digested the 6-kb DNA insert from pTM4 with TaqI under conditions which produced a spectrum of cleavage products ranging from completely digested to full-length 6-kb inserts. The DNA was then ligated into the ClaI site of pBR322. Trimethoprim-resistant colonies arising after transformation of competent E. coli with these mixtures were grown, and the plasmid DNA was isolated. Plasmids containing inserts ranging in size from approximately 1,600 to 3,500 base pairs (bp) were identified. The plasmid containing the smallest insert fragment, termed pTM10, was selected for sequence analysis (Fig. lc) .
DNA sequence analysis of a 1,626-bp fragment containing the type I Dhfr gene. The strategy used to sequence the insert is indicated in Fig.  2a . Briefly, the 1,626-bp fragment was digested with suitable restriction nucleases, and the products were inserted into phage M13 vectors mp8 and mp9 (12) . The inserts were then sequenced by the dideoxynucleotide chain termination method (12, 29) . The resulting sequence of the 1,626-bp fragment is shown in Fig. 2b [26] ) at an EcoRI site made blunt, using Klenow DNA polymerase I (20) .
The resulting plasmid, pR483trp (Fig. ld) , contains a Shine-Dalgarno sequence (31), a -35 region (14) , and a -10 region (28) from the trp promoter (20) fused directly to the R483 sequences. By inserting the HpaI fragment into a filled-in EcoRI site (5-AATTC...) following the trp promoter, the termination codon of the gene was restored. Plasmid pR483trp was introduced into competent cells, which were then plated onto medium containing various levels of trimethoprim. Only cells transformed with pR483trp produced trimethoprim-resistant colonies. Cells transformed with plasmid pR483trp grew in the presence of 0.5 mg of trimethoprim per ml (Table 1 ). In contrast, bacteria harboring either no plasmid or pSRCexl6 failed to grow in the presence of even 0.005 mg of trimethoprim per ml. Plasmid pR483trp conferred a resistance to trimethoprim identical to the trimethoprim resistance conferred by pRB483, pTM4, or pTM10, thereby localizing the trimethoprim-resistant Dhfr to this 490-bp DNA sequence.
To determine the sensitivity of the plasmidencoded Dhfr to trimethoprim, cells transformed with pR483trp were grown in minimal medium under conditions which induced high levels of transcription from the trp promoter (20) . An extract of these induced cells was prepared; when assayed for the reduction of dihydrofolate in the presence of NADPH, we observed that a level of 56 ,uM trimethoprim inhibited the Dhfr activity by 50% (Fig. 3) , a value virtually identical to that previously reported for the R483-encoded enzyme (27) . Control cultures induced under the same conditions did not produce detectable levels of Dhfr. Proteins from these same induced cell extracts were analyzed on sodium dodecyl sulfate-polyacrylamide gels; a protein with an apparent molecular weight of 17,000 was observed in induced cultures containing plasmid pR483 but not in induced control cultures (data not shown).
We have been unable to determine the identity of the second putative gene contained within the 1,626-bp insert of pTM10. We have observed that the streptomycin resistance marker, which is contained in plasmids pRB483 and pTM4, is not found in either pTM10 or pR483trp (data not shown), and no significant homologies were noted when a computer-assisted search of known protein sequences was performed.
Comparison of the predicted protein sequence of the type I enzyme with those of Dhfrs. The amino acid sequence of the type I enzyme, as derived from the DNA sequence, was compared (36) with the reported amino acid sequences of Dhfrs from E. coli (38) . Lactobacillus casei (9), Streptococcus faecium (19) , and methotrexateresistant murine tissue culture cells (13) (Fig. 4) (20) . Extracts (0.5 ml each) were prepared from 10 ml of induced cells as described previously (4). The reduction of dihydrofolate to tetrahydrofolate at 340 nm (23) was measured in increasing levels of trimethoprim (22, 26) and plotted as shown.
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The sequence of the mouse S-180 cell line enzyme has been deduced from its nucleotide sequence (13) , and is virtually identical to that of the mouse L1210 enzyme (37) . The sequence of the E. coli, S. faecium, and L. casei enzymes were obtained by direct sequence analysis of the purified polypeptides (9, 19, 38) . Symbols: *, residues homologous to the R483 enzyme; U, residues which are common to all five enzymes; 0, homologous residues which are common to four of the Dhfrs; 0, homologous residues found in three-fifths of the Dhfrs. The regions of the enzyme forming the hydrophobic binding pocket (24) are underlined. the type I Dhfr, our assignment of the N-terminal residues is based upon utilization of the ATG codon located at position 994. It should be noted that a slightly longer polypeptide may represent the primary translational product of the R483-encoded Dhfr in the event that the GTG codon, located 15 nucleotides 5' of the presumed initiator ATG at position 994, is utilized as the translational initiation codon. If so, such a polypeptide would be identical to that proposed in Fig. 2b except for the presence offive additional amino acids (Val-Lys-Leu-Ser-Leu-) at the amino terminus. The comparison in Fig. 4 shows that there is a significant degree (22 to 29%) of overall homology between the bacterial trimethoprim-sensitive enzymes and the type I enzyme. Surprisingly, the type I enzyme displays as much homology to the murine enzyme as to the procaryotic enzymes. (17) . These results suggest that the native form of the type I enzyme, which has a molecular weight of 35,000 (27) , is composed of two identical subunits.
DISCUSSION
Preceding the open reading frame are sequences conforming to the canonical description of bacterial promoters, such as the -35 region (5'TTGACA) (14) and the -10 region (5'-TA-TAAT) (28) . Upstream from the proposed translational initiation codon is a sequence (5'-AGGA) which may act as a ribosome binding site (31) , although the distance between this presumed Shine-Dalgarno site and the initiator methionine is longer than that usually observed (22 bp) (14) . In this context it is possible that the in-phase GTG codon (valine), located 7 (27) . A comparison of the amino acid sequence of the type I Dhfr with other procaryotic and eucaryotic Dhfrs (36) reveals that the R483-encoded Dhfr has 22 to 29% of its amino acids in common with other Dhfrs, a homology sufficient to indicate a genuine relationship (15) . It is notable that the degree to which the various bacterial Dhfrs are related is much less than that observed for Dhfrs from avian species and a wide variety of mammalian species (41) . Approximately 70%o of the residues which are conserved (to a level of 60% or greater) among the five different Dhfrs are found in the four regions (A, B, C, and D, Fig. 4 ) which have been shown to form the hydrophobic binding site of the enzyme (25) . X-ray crystallographic studies have shown that methotrexate, and by analogy, trimethoprim and the substrate dihydrofolate, occupies a cleft formed by these regions (41) .
Although it is possible that the trimethoprim resistance marker of Tn7 originated from an E. coli chromosomal gene, such a conclusion is not supported by a comparison of the amino acid sequences of the various Dhfrs, in that the type I Dhfr is no more similar to the E. coli enzyme than to other bacterial Dhfrs or even to the murine enzyme. Furthermore, an examination of the nucleotide sequences comprising the 1,626-bp fragment encoding the type I enzyme reveals little homology to the sequences which constitute and surround the chromosomally encoded E. coli Dhfr (34) . In view of the observation that the drug sensitivity of a bacterial (5) and a mammalian (32) Dhfr can be profoundly affected by a single amino acid substitution, the extensive structural dissimilarities between the type I Dhfr and the bacterial enzymes make it difficult to assess which changes in the binding site reflect the functional changes in the properties of the enzyme. Clarification of this issue, as well as an appreciation of the phylogeny of the type I Dhfr, must await analyses of similar enzymes from additional sources.
